Nephron sparing surgery for the treatment of renal masses: A single center experience.

Nephron sparing surgery renal cancer renal cell carcinoma robotics small renal masses

Journal

Urologia
ISSN: 1724-6075
Titre abrégé: Urologia
Pays: United States
ID NLM: 0417372

Informations de publication

Date de publication:
Aug 2021
Historique:
pubmed: 11 2 2021
medline: 29 10 2021
entrez: 10 2 2021
Statut: ppublish

Résumé

Nowadays, the partial nephrectomy (PN) not only is considered oncological equivalent to radical nephrectomy as renal tumor's treatment, but has also give benefits in quality of life and overall survival of patients. The primary objective of the present study was to report our single center experience with NSS, predominantly performed by a robot assisted access, in a high-volume center with large experience with minimally invasive surgery. Between June 2018 and January 2020, a consecutive series of 109 patients (pts) with a renal mass suspicious of renal cell carcinoma, feasible of NSS, detected by ultrasound and abdominal computed tomography (CT), underwent NSS and they were included in a prospectively maintained institutional database. Baseline demographics and clinical characteristics, perioperative and postoperative parameters, pathological data were recorded. The mean clinical maximum CT tumor diameter was 37.3 ± 19.6 mm (median 31.5 mm; interquartile range 25-45 mm). PADUA risk was low in 54 pts (49.5%), intermediate in 48 pts (44.0%), high in seven pts (6.4%). The clinical T stage was mostly pT1a (70.6%). NSS was performed by open surgery in nine pts (8.3%), laparoscopy in one pts (0.9%) and was robot assisted in 99 pts (90.8%). A simple enucleation was performed in 67 pts (61.5%), an enucleoresection was performed in 37 pts (33.9%) and a partial nephrectomy was performed in five pts (4.6%). Warm ischemia was performed in 41 pts (37.6%), with a mean warm ischemia time of 5.1 ± 7.1 min. The mean pathological maximum tumor diameter was 35.5 ± 21.7 mm (median 30 mm; interquartile range 22-40 mm). Overall PSM rate was 11.9% (13 pts). In 78% of cases no complication was recorded. No major complications (grade III-IV-V) were noted. Our findings suggest that NSS is a safe, reproducible and minimally invasive approach as treatment of small renal masses. NSS permits to achieve a fine oncological management without any worsening of renal function.

Sections du résumé

BACKGROUND BACKGROUND
Nowadays, the partial nephrectomy (PN) not only is considered oncological equivalent to radical nephrectomy as renal tumor's treatment, but has also give benefits in quality of life and overall survival of patients.
OBJECTIVES OBJECTIVE
The primary objective of the present study was to report our single center experience with NSS, predominantly performed by a robot assisted access, in a high-volume center with large experience with minimally invasive surgery.
METHODS METHODS
Between June 2018 and January 2020, a consecutive series of 109 patients (pts) with a renal mass suspicious of renal cell carcinoma, feasible of NSS, detected by ultrasound and abdominal computed tomography (CT), underwent NSS and they were included in a prospectively maintained institutional database. Baseline demographics and clinical characteristics, perioperative and postoperative parameters, pathological data were recorded.
RESULTS RESULTS
The mean clinical maximum CT tumor diameter was 37.3 ± 19.6 mm (median 31.5 mm; interquartile range 25-45 mm). PADUA risk was low in 54 pts (49.5%), intermediate in 48 pts (44.0%), high in seven pts (6.4%). The clinical T stage was mostly pT1a (70.6%). NSS was performed by open surgery in nine pts (8.3%), laparoscopy in one pts (0.9%) and was robot assisted in 99 pts (90.8%). A simple enucleation was performed in 67 pts (61.5%), an enucleoresection was performed in 37 pts (33.9%) and a partial nephrectomy was performed in five pts (4.6%). Warm ischemia was performed in 41 pts (37.6%), with a mean warm ischemia time of 5.1 ± 7.1 min. The mean pathological maximum tumor diameter was 35.5 ± 21.7 mm (median 30 mm; interquartile range 22-40 mm). Overall PSM rate was 11.9% (13 pts). In 78% of cases no complication was recorded. No major complications (grade III-IV-V) were noted.
CONCLUSION CONCLUSIONS
Our findings suggest that NSS is a safe, reproducible and minimally invasive approach as treatment of small renal masses. NSS permits to achieve a fine oncological management without any worsening of renal function.

Identifiants

pubmed: 33565363
doi: 10.1177/0391560321993557
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

206-211

Auteurs

Michele Zazzara (M)

Department of Urology, Ente Ecclesiastico Ospedale Generale Regionale "F. Miulli," Acquaviva delle Fonti, Bari, Italy.

Roberto Carando (R)

Klinik für Urologie, Luzerner Kantonsspital, Lucerne, Switzerland.
Clinica Luganese Moncucco, Lugano, Switzerland.
Clinica S. Anna, Sorengo, Switzerland.
Clinica S. Chiara, Locarno, Switzerland.

Arjan Nazaraj (A)

Department of Urology, Ente Ecclesiastico Ospedale Generale Regionale "F. Miulli," Acquaviva delle Fonti, Bari, Italy.

Marcello Scarcia (M)

Department of Urology, Ente Ecclesiastico Ospedale Generale Regionale "F. Miulli," Acquaviva delle Fonti, Bari, Italy.

Michele Romano (M)

Department of Urology, Ente Ecclesiastico Ospedale Generale Regionale "F. Miulli," Acquaviva delle Fonti, Bari, Italy.

Giuseppe Mario Ludovico (GM)

Department of Urology, Ente Ecclesiastico Ospedale Generale Regionale "F. Miulli," Acquaviva delle Fonti, Bari, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH